Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.
about
Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population.PEGylated Biopharmaceuticals: Current Experience and Considerations for Nonclinical Development.How I treat acute lymphoblastic leukemia in older adolescents and young adultsGenome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemiaPilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology GroupRheumatic symptoms in childhood leukaemia and lymphoma-a ten-year retrospective study.Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001Association Between N363S and BclI Polymorphisms of the Glucocorticoid Receptor Gene (NR3C1) and Glucocorticoid Side Effects During Childhood Acute Lymphoblastic Leukemia Treatment.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Outcomes for children and adolescents with cancer: challenges for the twenty-first century.A phase I/II study of the safety and efficacy of the addition of sirolimus to tacrolimus/methotrexate graft versus host disease prophylaxis after allogeneic haematopoietic cell transplantation in paediatric acute lymphoblastic leukaemia (ALL).Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: a Children's Oncology Group Report.MiR-99a may serve as a potential oncogene in pediatric myeloid leukemiaEarly Response to Dexamethasone as Prognostic Factor: Result from Indonesian Childhood WK-ALL Protocol in YogyakartaRole of the erythropoietin receptor in ETV6/RUNX1-positive acute lymphoblastic leukemia.Early response to chemotherapy as a prognostic factor in childhood acute lymphoblastic leukaemia: a methodological review.Susceptibility to 6-MP toxicity conferred by a NUDT15 variant in Japanese children with acute lymphoblastic leukaemia.High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology groupDrug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation.The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemiaPotential toxicities of prophylactic cranial irradiation.Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemiaGlucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cells.The best way to use asparaginase in childhood acute lymphatic leukaemia--still to be defined?Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer.Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404).Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201.Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.Acute lymphoblastic leukemia and Klinefelter syndrome in children: two cases and review of the literature.Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemiaClinical trials in paediatric haematology-oncology: are future successes threatened by the EU directive on the conduct of clinical trials?Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia.Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235Thiopurine methyltransferase and treatment outcome in the UK acute lymphoblastic leukaemia trial ALL2003.An approach to the management of leukemia in the developing world.Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.Survival following relapse in childhood haematological malignancies diagnosed in 1974-2003 in Yorkshire, UKGlucocorticoid-induced apoptosis of healthy and malignant lymphocytes.
P2860
Q24814207-7D489232-9E8D-4E25-92C9-7B767DB7BB75Q27691352-25F7505B-CB66-4614-A6B4-210710D54580Q28087589-34397112-5458-4588-B253-159A687BDE4EQ28943431-FE6E7484-12C1-4132-B83D-C40FF19D3C13Q30417943-DE3B2FA1-5F6C-4F47-A8D8-E833B46CF6F9Q33407472-92C3B344-2A0D-4500-A426-5D979960204EQ33647139-E35369A7-4CBA-47C6-B493-F024EE143B62Q33716500-2B4066C4-E45D-4B93-A030-CF7D33B27F13Q33770150-C2DA3D0F-1397-4B89-AA25-014670F037CAQ33897659-41063A83-A3CC-431F-8A59-3BDABBAECC67Q33924570-B322BAD3-17D0-4140-B43D-220BB74F20CCQ34003323-EA344355-960B-49F5-83A2-8EDF4472C123Q34251541-F91E9D45-C7BF-40AE-8E40-17C1F8CF48FDQ34252624-63CFBD0B-86DB-4FA6-8CEA-CCD47A334EF2Q34326017-D62D33EC-B595-4211-BABD-B3C583159021Q34448334-8DD1369B-5FB2-4798-BB7E-8E5E8EB7EC19Q34478851-ACB18CA1-4852-4625-982C-E45C4DF284CAQ34645259-7F27D642-9E89-4CEB-A52D-5061A12B01CAQ34992080-D312BDB0-BB82-4A6C-890A-0DA4127EFA4BQ35025684-35FD9B68-01A4-41C7-86DE-9DF04D59C46AQ35089181-09806252-9DEA-4F50-B581-AE8BE95B0D4FQ35094049-431DA76B-D0AD-4B3E-AEF1-C94049F6BB0BQ35200326-DCBF6A51-DF47-4DAA-BBF9-331632F85926Q35616085-696787CD-B79E-4B7E-856B-F9CA48017F1EQ35664297-1F976925-5A29-47C9-BF1F-D1B8DD546AFDQ35732108-E5E0C6C0-D19A-475C-9E5C-E33D3ADFC217Q35754395-CA25824B-2DD5-4DD6-A293-F45CA1673973Q35797649-5FB799FE-8B59-4D34-821A-453A8D415E5DQ35925012-2B03B40B-0BAE-4AC2-BF7E-1765FA5B8DCAQ35989461-842BDA80-5BA5-48C0-9AD8-3AE638C8951AQ35996675-383EB07F-75A9-4ECD-9E71-EC7503F5A861Q36094717-60A2D8E1-DC54-4890-A6A0-37D0E1E7413BQ36155005-2B594C4F-5CAD-4EBB-BDC4-335555002F5AQ36200481-FABB7FBF-2258-4CC9-845E-147A49866DF4Q36378398-D494E052-F2BC-4DAE-8E1E-E2089079F51CQ36393968-F7589580-8AED-4B9B-B6AE-8A19D8B70226Q36481195-F8204F2C-FFC5-4443-8723-6C0BBA7CCE22Q36532537-55C3D384-D4D3-40DC-ABB2-A781E8D5762BQ36610199-5EDA396C-17DF-4405-840E-A7BD675C02F4Q36628641-4EE4C580-4197-413D-8E44-0A8EC05069C8
P2860
Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@en
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@nl
type
label
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@en
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@nl
prefLabel
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@en
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@nl
P2093
P356
P1433
P1476
Long-term results of four cons ...... 995. Berlin-Frankfurt-Münster.
@en
P2093
Odenwald E
Schrappe M
Zimmermann M
P2888
P304
P356
10.1038/SJ.LEU.2401973
P577
2000-12-01T00:00:00Z